Bristol-Myers Squibb has reported that the Phase III CheckMate -026 trial of Opdivo (nivolumab) has failed to meet the primary endpoint of progression-free survival in patients with previously untreated, advanced non-small-cell lung cancer (NSCLC).
Opdivo is an PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1, which is used by the cancer cells to take refuge from the immune system and block the tumour from being exposed to it.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It prevents the binding of PD-L1 and PD-L2, blocking the PD-1 pathway's suppressive signalling on the immune system including the interference with an anti-tumour immune response.
The open-label, randomised Phase III CheckMate 026 trial was designed to measure the efficacy of Opdivo as monotherapy against a chemotherapy regimen of the investigator’s choice to treat NSCLC.
The trial involved 541 patients who had no history of prior systemic treatment for advanced disease and tested positive for PD-L1 expression of the tumours.
It was primarily focused to determine the progression-free survival resulted by the administration of Opdivo, which was not met by the study.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBristol-Myers Squibb CEO Giovanni Caforio said: “While we are disappointed CheckMate -026 did not meet its primary endpoint in this broad patient population, we remain committed to improving patient outcomes through our comprehensive development programme, including the ongoing Phase III CheckMate -227 study exploring the potential of the combination of Opdivo plus Yervoy for PD-L1 positive patients, and Opdivo plus Yervoy, or Opdivo plus chemotherapy in PD-L1 negative patients.”
The company will fully examine the CheckMate -026 trial data and collaborate with the investigators for future presentation of the results.
